Different family caregiver- and care recipient-related factors are associated with the cost of care in the early, mild, and moderate stages of Alzheimer's disease in Finland: A 5-year ALSOVA study.
Viivi Jetsonen, Tarja Välimäki, Tuomas Selander, Virpi Kuvaja-Köllner, Janne Martikainen, Anne M Koivisto
{"title":"Different family caregiver- and care recipient-related factors are associated with the cost of care in the early, mild, and moderate stages of Alzheimer's disease in Finland: A 5-year ALSOVA study.","authors":"Viivi Jetsonen, Tarja Välimäki, Tuomas Selander, Virpi Kuvaja-Köllner, Janne Martikainen, Anne M Koivisto","doi":"10.1007/s10198-026-01950-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Alzheimer's disease (AD) accounts for a significant proportion of health and social care costs. We studied family caregiver (FC), care recipient (CR), and formal care provider-related factors, which are associated with the cost of care in different stages of AD in Finland.</p><p><strong>Methods: </strong>A 5-year follow-up was conducted with 231 individuals with AD (CRs) and their FCs as a part of the ALSOVA project. The data was collected between 2002 and 06. Significant factors associated with costs were identified using a stepwise backward elimination procedure. Neuropsychiatric symptoms were measured with the Neuropsychiatric Inventory (NPI).</p><p><strong>Results: </strong>Across all stages of AD, each additional year of CR's education was associated with a 3.4% reduction in costs (rate ratio [RR] 0.966, 95% CI 0.940-0.993). Conversely, a one-point increase on the Neuropsychiatric Inventory was associated with a 1.8% increase in costs (RR 1.018, 95% CI 1.011-1.025). CR's neuropsychiatric symptoms (RR 1.028, 95% CI 1.010-1.047) and male FC (RR 1.756, 95% CI 1.266-2.437) were associated with increased total costs in early AD, CR's comorbidities (RR 1.138, 95% CI 1.068-1.212) and FC's burden (RR 1.032, 95% CI 1.012-1.053) in mild AD and FC being a spouse (RR 1.451, 95% CI 1.105-1.905) in moderate AD. No formal care provider-related factors were associated with total costs in any stage of AD.</p><p><strong>Conclusions: </strong>This study reveals several factors that may be manageable to control the costs of AD. Comprehensive prevention, evaluation, and treatment of a CR's neuropsychiatric symptoms and comorbidities should be executed early. Informal care can act as a substitute for formal care in early-stage AD, and supportive measures toward FCs should be considered.</p>","PeriodicalId":51416,"journal":{"name":"European Journal of Health Economics","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2026-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Health Economics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10198-026-01950-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ECONOMICS","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: Alzheimer's disease (AD) accounts for a significant proportion of health and social care costs. We studied family caregiver (FC), care recipient (CR), and formal care provider-related factors, which are associated with the cost of care in different stages of AD in Finland.
Methods: A 5-year follow-up was conducted with 231 individuals with AD (CRs) and their FCs as a part of the ALSOVA project. The data was collected between 2002 and 06. Significant factors associated with costs were identified using a stepwise backward elimination procedure. Neuropsychiatric symptoms were measured with the Neuropsychiatric Inventory (NPI).
Results: Across all stages of AD, each additional year of CR's education was associated with a 3.4% reduction in costs (rate ratio [RR] 0.966, 95% CI 0.940-0.993). Conversely, a one-point increase on the Neuropsychiatric Inventory was associated with a 1.8% increase in costs (RR 1.018, 95% CI 1.011-1.025). CR's neuropsychiatric symptoms (RR 1.028, 95% CI 1.010-1.047) and male FC (RR 1.756, 95% CI 1.266-2.437) were associated with increased total costs in early AD, CR's comorbidities (RR 1.138, 95% CI 1.068-1.212) and FC's burden (RR 1.032, 95% CI 1.012-1.053) in mild AD and FC being a spouse (RR 1.451, 95% CI 1.105-1.905) in moderate AD. No formal care provider-related factors were associated with total costs in any stage of AD.
Conclusions: This study reveals several factors that may be manageable to control the costs of AD. Comprehensive prevention, evaluation, and treatment of a CR's neuropsychiatric symptoms and comorbidities should be executed early. Informal care can act as a substitute for formal care in early-stage AD, and supportive measures toward FCs should be considered.
目的:阿尔茨海默病(AD)占健康和社会护理费用的很大比例。我们研究了家庭照顾者(FC)、照顾者(CR)和正规护理提供者相关因素,这些因素与芬兰AD不同阶段的护理成本相关。方法:作为ALSOVA项目的一部分,对231例AD (CRs)患者及其FCs进行了为期5年的随访。这些数据是在2002年至2006年间收集的。使用逐步逆向消除程序确定与成本相关的重要因素。用神经精神量表(NPI)测量神经精神症状。结果:在AD的所有阶段,每增加一年CR的教育与3.4%的成本降低相关(比率比[RR] 0.966, 95% CI 0.940-0.993)。相反,神经精神量表每增加1分,费用增加1.8% (RR 1.018, 95% CI 1.011-1.025)。CR的神经精神症状(RR 1.028, 95% CI 1.010-1.047)和男性FC (RR 1.756, 95% CI 1.266-2.437)与早期阿尔茨海默病总费用增加、轻度阿尔茨海默病CR的合并症(RR 1.138, 95% CI 1.068-1.212)和中度阿尔茨海默病FC的负担(RR 1.032, 95% CI 1.012-1.053)和FC为配偶(RR 1.451, 95% CI 1.105-1.905)相关。在阿尔茨海默病的任何阶段,与正式护理提供者相关的因素都与总成本无关。结论:本研究揭示了几个可以控制AD成本的因素。综合预防、评估和治疗CR的神经精神症状和合并症应及早执行。在早期AD患者中,非正式护理可替代正式护理,应考虑对FCs采取支持性措施。
期刊介绍:
The European Journal of Health Economics is a journal of Health Economics and associated disciplines. The growing demand for health economics and the introduction of new guidelines in various European countries were the motivation to generate a highly scientific and at the same time practice oriented journal considering the requirements of various health care systems in Europe. The international scientific board of opinion leaders guarantees high-quality, peer-reviewed publications as well as articles for pragmatic approaches in the field of health economics. We intend to cover all aspects of health economics:
• Basics of health economic approaches and methods
• Pharmacoeconomics
• Health Care Systems
• Pricing and Reimbursement Systems
• Quality-of-Life-Studies The editors reserve the right to reject manuscripts that do not comply with the above-mentioned requirements. The author will be held responsible for false statements or for failure to fulfill the above-mentioned requirements.
Officially cited as: Eur J Health Econ